Nonsteroidal anti-inflammatory drugs and prostate cancer: A systematic review of the literature and meta-analysis

Journal of the Canadian Urological Association

Volumn 3, Issue 4, 2009, Pages 323-330

  Jafari, Siavash ^a   Etminan, Mahyar ^a,b   Afshar, Kourosh ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centre for Clinical Epidemiology and Evaluation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450194837     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.1129     Document Type: Review

References (45)

1. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-8160
2. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224
3. Narayanan BA, Narayanan NK, Pttman B, et al. Adenocarcina of the mouse prostate growth inhibition by Celecoxib: down regulation of transcription factors involved in COX-2 inhibition. Prostate 2006; 66:257-265
4. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002;13:72-79
5. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78-83.
6. Roberts OR, Jacobson DJ, Girman CJ, et al. Prostate cancer and non-steroid anti-inflammatory drugs: a protective association. Proceedings of the American Association for Cancer Research Annual Meeting; 2001 Mar. 24-28; New Orleans: MN Merck Research Laboratories. p. 767.
7. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004;90:93-99
8. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6. In: The Cochrane Library, Issue 4. Chichester (UK): John Wiley & Sons, Ltd; 2006.
9. Lichtenstein MJ, Mulrow CD, Elwood PC. Guidelines for reading case-control studies. J Chronic Dis 1987; 40:893-903.
10. Duval SJ, Tweedie RL. A non-parametric "trim and fill" method of accounting for publication bias in metaanalysis. J Am Stat Assoc 2000;95:89.
11. Bosetti C, Talamini R, Negri E, et al. Aspirin and the risk of prostate cancer. Eur J Cancer Prev 2006; 15:43-45
12. Dasgupta K, Di Cesar D, Ghosn J, et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006;12:130-135
13. Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:649-653
14. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002;13:427-434
15. Irani J, Ravery V, Pariente JL, et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2002;168:1985-1988
16. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005;97:975-980 (Pubitemid 41430563)
17. Langman MJ, Cheng KK, Gilman EA, et al: Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2001;320:1642.
18. Leitzmann MF, Stampfer MJ, Ma J, et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1108-1111
19. Liu X, Plummer SJ, Nock NL, et al. Nonsteroidal anti-inflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 2006;164:984-989
20. Mahmud SM, Tanguayb S. Bégin LR, et al. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 2006;15:158-164
21. Menezes RJ, Swede H, Mettlin C, et al. Regular aspirin use and risk of prostate cancer. Cancer Causes Control 2006;17:251-256
22. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7:169-170
23. Neugut AI, Rosenberg DJ, Ahsan H, et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998;7:869-873
24. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-515
25. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-1250
26. Perron L, Bairati I, Moore L, et al. Dosage, duration and timing of nonsteroidal anti-inflammatory drug use and risk of prostate cancer. Int J Cancer 2003;106:409-415
27. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219-225
28. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-146
29. Sørensen HT, Friis S, Nørgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-1692
30. Platz EA, Rohrmann S, Pearson JD, et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005;14:390-396
31. Narayanan BA, Narayanan NK, Pittman P, et al. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti inflammatory drugs is linked to the sequential effect on androgen receptor, vasculoendothelial growth factor, cyclooxygenases and AKT signaling in TRAMP model. Clin Cancer Res 2004;10:7727-7737
32. Palapattu G. S., Sutcliffe S., Bastian P. J., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-1181
33. Gupta S, Ahmad N, Marengo SR, et al. Chemoprevention of prostate carcinogenesis by adifluoromethylornithine in TRAMP mice. Cancer Res 2000;60:5125-5133
34. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000;56:671-676
35. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000; 86: 736-741
36. Tanji N, Kikugawa T, Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. Anticancer Res 2000; 20: 2313-2319
37. Narayanan BA, Condon MS, Bosland MC, et al. Suppression of N-methyl-N-nitrosourea (MNU)/testosterone-induced rat prostate cancer growth by celecoxib: effects on COX-2, cell cycle regulation and apoptosis mechanism(s). Clin Cancer Res 2003;9:3503-3513
38. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplement of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64:3334-3343
39. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
40. Stock DC, Groome PA, Siemens DR, et al. Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer. Prostate 2008;68:1655-1665
41. Stock D, Groome PA, Siemens DR. Inflammation and prostate cancer: A future target for prevention and therapy? Urol Clin North Am 2008;35:117-130
42. Pruthi RS, Derksen JE, Moore D, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006; 12:2172-2177
43. Walter SD. Recall bias in epidemiologic studies. J Clin Epidemiol 1990;43:1431-1432
44. Sackett DL. Bias in analytical research. J Chronic Dis 1979;32:51-63.
45. Smith GD, Phillips AN. Confounding in epidemiological studies: why "independent" effects may not be all they seem. BMJ 1992;305:757-759